IAM-C1
/ Iambic Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 18, 2024
Iambic Therapeutics to Present at the 43rd Annual JP Morgan Healthcare Conference
(Businesswire)
- "Dr. Miller will detail progress and anticipated milestones for Iambic’s emerging pipeline of development candidates, as well as advances to its AI drug discovery platform. The Company’s pipeline currently includes IAM1363, a highly selective, brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1/1b study, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs."
Clinical • Oncology • Solid Tumor
October 03, 2023
Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA
(Businesswire)
- "Funding will Support Continued AI Platform Innovations and Advancement of Multiple Candidates into Clinical Development, Including IAM-H1, a Selective Brain-Penetrant HER2 Inhibitor, and IAM-C1, a Selective Dual CDK2/4 Inhibitor."
Commercial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1